BioCardia Reports 2025 Business Highlights and Financial Results: Advancing CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia reported 2025 business highlights and financial results. The company is advancing the regulatory discussions with the USA FDA and Japan PMDA on the potential market release of the CardiAMP System for treating ischemic heart failure. Four centers are actively enrolling in the CardiAMP HF II clinical study, and the PMDA granted a preliminary clinical consultation on the acceptability of the existing CardiAMP HF clinical data. The company also presented echocardiography clinical results at the Technology and Heart Failure Therapeutics conference in Boston, showing positive evidence of decreased pathological left ventricular remodeling in patients receiving CardiAMP cell therapy treatment.